WO2006017861A3 - Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists - Google Patents

Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists Download PDF

Info

Publication number
WO2006017861A3
WO2006017861A3 PCT/US2005/029286 US2005029286W WO2006017861A3 WO 2006017861 A3 WO2006017861 A3 WO 2006017861A3 US 2005029286 W US2005029286 W US 2005029286W WO 2006017861 A3 WO2006017861 A3 WO 2006017861A3
Authority
WO
WIPO (PCT)
Prior art keywords
meth
antagonist
methamphetamine
methods
addiction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/029286
Other languages
French (fr)
Other versions
WO2006017861A2 (en
Inventor
Clark E Tedford
Tavye Celeste Napier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loyola University Chicago
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Loyola University Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Medical Systems Inc, Loyola University Chicago filed Critical Omeros Medical Systems Inc
Priority to CA002575995A priority Critical patent/CA2575995A1/en
Priority to EP05809908A priority patent/EP1776121A2/en
Publication of WO2006017861A2 publication Critical patent/WO2006017861A2/en
Publication of WO2006017861A3 publication Critical patent/WO2006017861A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods for screening specific biological endpoints that can be utilized to identify potential therapeutic agents for METH addiction. In one aspect of the invention, the methods involve reversal of behavioral sensitization and/or conditioned place preference in an animal previously treated with METH in the presence of a known amount of a 5-HT2A/2C antagonist or a selective 5-HT2C antagonist, and reversal of the electrophysiological endpoints in a METH-treated animal in the presence of a known amount of the 5-HT2A/2C antagonist or the selective 5-HT2C antagonist. Therapeutic treatment methods for reversing the set of biological endpoints that change in the METH drug addict using mirtazapine, SDZ SER 082, and related serotonin antagonists are also provided. The methods of the invention may be utilized in the identification of potential new therapies for multiple drugs of abuse.
PCT/US2005/029286 2004-08-13 2005-08-15 Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists Ceased WO2006017861A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002575995A CA2575995A1 (en) 2004-08-13 2005-08-15 Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
EP05809908A EP1776121A2 (en) 2004-08-13 2005-08-15 Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60169004P 2004-08-13 2004-08-13
US60/601,690 2004-08-13

Publications (2)

Publication Number Publication Date
WO2006017861A2 WO2006017861A2 (en) 2006-02-16
WO2006017861A3 true WO2006017861A3 (en) 2006-09-14

Family

ID=35839994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/029286 Ceased WO2006017861A2 (en) 2004-08-13 2005-08-15 Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists

Country Status (4)

Country Link
US (1) US20060035889A1 (en)
EP (1) EP1776121A2 (en)
CA (1) CA2575995A1 (en)
WO (1) WO2006017861A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004100899A2 (en) * 2003-05-13 2004-11-25 The Mclean Hospital Corporation Use of secretin in treatments of disorders associated with the amygdala
JP2008509925A (en) * 2004-08-13 2008-04-03 オメロス コーポレイション Novel serotonin receptor ligands and their use
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3053440B1 (en) * 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
FR2976807B1 (en) * 2011-06-24 2013-07-05 Greenpharma Sas PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DEPENDENCE IN HUMAN BEINGS
WO2013148572A1 (en) * 2012-03-27 2013-10-03 Albany Medical College Blocking of cue-induced drug reinstatement
CN105527136B (en) * 2014-10-23 2019-02-22 复旦大学 A pretreatment method for detecting veterinary drug residues in animal tissues
WO2016138357A1 (en) 2015-02-27 2016-09-01 Kindred Biosciences, Inc. Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
US11999676B2 (en) 2016-04-21 2024-06-04 University Of Kentucky Research Foundation Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
US10668030B2 (en) * 2016-04-21 2020-06-02 University Of Kentucky Research Foundation Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
WO2021195427A1 (en) * 2020-03-25 2021-09-30 Ch Tac, Llc 2-bromo-lysergic acid diethylamide for substance abuse
CN112715474B (en) * 2020-12-25 2022-10-04 江汉大学 Method for forming animal model with conditional site preference by induction of arecoline and menthol and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998139A (en) * 1997-04-10 1999-12-07 The Regents Of The University Of California Assay for determination of neuronal activity in brain tissue
US6150353A (en) * 1997-03-27 2000-11-21 Akzo Nobel N.V. Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
WO2004082584A2 (en) * 2003-03-21 2004-09-30 Curidium Limited 5ht2c receptor antagonists in the treatment of schizophrenia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150353A (en) * 1997-03-27 2000-11-21 Akzo Nobel N.V. Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
US5998139A (en) * 1997-04-10 1999-12-07 The Regents Of The University Of California Assay for determination of neuronal activity in brain tissue
WO2004082584A2 (en) * 2003-03-21 2004-09-30 Curidium Limited 5ht2c receptor antagonists in the treatment of schizophrenia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] BRUINVELS: "5HT2C Receptor Antagonists in the Treatment of Schizophrenia", XP008113827, accession no. STN Database accession no. (2004:799435) *

Also Published As

Publication number Publication date
EP1776121A2 (en) 2007-04-25
CA2575995A1 (en) 2006-02-16
US20060035889A1 (en) 2006-02-16
WO2006017861A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2005107726A3 (en) Method for the treatment of back pain
CY2022031I2 (en) NOVEL BINDERS THAT CONFIGURE RΑR RECEPTORS, AND THEIR USE IN HUMAN MEDICINE AND COSMETICS
WO2006017861A3 (en) Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
FR2873691B1 (en) AMINO-PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
NO20052496D0 (en) Selected CGRP antagonists, methods for their preparation and use thereof as drugs.
FR2854158B1 (en) 2-ACYLAMINO-4-PHENYLETHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
PL376373A1 (en) Selected cgrp antagonists, method for production and use thereof as medicament
DE602004005076D1 (en) COEXTRUDED SAFETY DOSAGE FORM WITH AN ACTIVE AGENT AND ADVERSE AGENT AND METHOD OF MANUFACTURING THEREOF
CY2014008I2 (en) QUINAZOLINE DERIVATIVES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE AND METHODS FOR THEIR PRODUCTION
IL166396A0 (en) Vanilloid receptor ligands and their use in treatments
FR2854633B1 (en) PIPERIDINYL-AND PIPERAZINYL-ALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
DE60234183D1 (en) USE OF METHYL NALTREXONE FOR THE TREATMENT OF IMMUNOSUPPRESSION
EP2486924A3 (en) Drugs and uses
MA28575B1 (en) 1-AMINO-PHTHALAZINE DERIVATIVES, THEIR PREPARATION, AND THERAPEUTIC USE THEREOF
AU2002339128A1 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
FR2866888B1 (en) ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
ATE399542T1 (en) ALFAVBETA3 AND ALFAVBETA6 INTEGRIN ANTAGONISTS AS ANTIFIBROTIC AGENTS
SI1276476T1 (en) Use of bradycardic substances in the treatment of myocardial diseases associated with hypertrophy, and new combinations of drugs
FR2850377B1 (en) ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2865205B1 (en) ARYLOXYALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
WO2002092016A3 (en) Therapeutic use of rank antagonists
NL1033403A1 (en) Therapeutic pyrazolo [3,4-b] pyridines and indazoles.
DE602004032178D1 (en) COMBINATION OF ROSCOVITINE AND CS-682 OR ITS METABOLITAN CNDAC
DK1626973T3 (en) (1S, 5S) -3- (5,6-dichloro-3-pyridinyl) -3,6-diazabicyclo [3.2.0] heptane with analgesic effect
FR2845388B1 (en) 1,4-DIAZABICYCLO [3.2.2] NONANECARBOXAMIDES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2575995

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005809908

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005809908

Country of ref document: EP